Page 26 - focusUnimore_giugno2023

Revolutionizing Clinical Trials through Innovation

and Excellence (REACT-X): un Centro per le

Sperimentazioni Cliniche

Revolutionizing Clinical Trials through Innovation and Excellence (REACT-X): a Clinical Trials Centre

The current era is characterised by medicine rapidly evolving towards translational, precision and predic-
tive approaches. Rapid and efficient clinical trials are the driving force behind the discovery of new drugs
and therapies. In particular, phase 1 and 2 clinical trials are crucial as they lead to innovative and safe trea
ments, new therapeutic indications and a deeper understanding of the pathophysiological mechanisms of
human diseases. This is the context for the University's strategic project “Revolutionizing Clinical Trials
through Innovation and Excellence (REACT-X)”, coordinated by Prof. Luca Pani, Professor of Pharmacol-
ogy at the Department of Biomedical, Metabolic and Neuroscience Sciences, Director General of the Italian
Medicines Agency (AIFA) and Italian representative to the European Medicines Agency (EMA), which aims to
create a centre of excellence in research and training in phase 1 and 2 clinical trials - Centro per Sperimen-
tazioni Cliniche, CSC. The centre will include a laboratory certified according to Good Laboratory Practice
(GLP), guaranteeing reliability and quality of results related to clinical trials. This is also the context of the
IMI2 FACILITATE European project, of which Unimore is leader, conceived by Prof. Pani and coordinated by
Prof. Johanna Blom, to create a sustainable regulatory, ethical and legally appropriate ecosystem for the
management and sharing of health data. The CSC will soon be a reference point within the European Union
for research and innovation in the field of clinical trials and health data management.

’epoca attuale è caratterizza- cliniche rapide ed efficienti rappresentano il mo-
ta da una medicina che evolve tore trainante per la scoperta di nuovi farmaci e
rapidamente verso approcci terapie. In particolare, gli studi clinici di fase 1 e
traslazionali, di precisione e pre- 2 sono fondamentali, poiché portano a trat-
Ldittivi. In tale contesto, è fonda- tamenti innovativi e sicuri, nuove indicazioni
mentale che le strutture ospedaliere e gli istituti di terapeutiche e una comprensione più profonda dei
istruzione superiore siano in grado di sviluppare meccanismi fisiopatologici delle malattie umane.
competenze scientifiche e mediche adeguate ad In questo contesto di riferimento si inserisce

affrontare in modo efficace e proattivo le nuove il progetto strategico di Ateneo “Revolutioni-
sfide che si presentano. zing Clinical Trials through Innovation and

Come dimostrato dalla ricerca e sviluppo di pro- Excellence (REACT-X)” coordinato dal Prof.
dotti medicinali per il Covid-19, le sperimentazioni Luca Pani, ordinario di Farmacologia presso il

26